Latest Health News

Apiam Animal Health Limited has announced a special fully franked dividend of AUD 0.10 per share, with payment scheduled for mid-February 2026. Notably, the company has suspended its dividend reinvestment plan for this payout.

Apiam Animal Health has announced a fully franked special dividend of 10 cents per share, payable before the completion of its proposed acquisition by Adamantem Capital entities. The dividend is conditional on the scheme’s effectiveness and offers shareholders potential tax benefits through franking credits.

Regal Partners has launched a $75 million on-market share buy-back program, signalling strong confidence in its financial health and growth prospects. The buy-back aims to enhance shareholder value while preserving capital for strategic opportunities.

Environmental Clean Technologies Limited (ECT) has made significant progress in developing its Rapid Electrothermal Mineralisation (REM) technology, aiming to provide a scalable, in-situ solution for permanently destroying PFAS contamination in soil.

Beach Energy’s FY26 half-year results reveal steady sales volumes and a robust ramp-up at the Waitsia Gas Plant, supported by strong LNG cargo revenues and disciplined cost management.

BCAL Diagnostics has launched its Avantect blood tests for pancreatic and ovarian cancer with encouraging early uptake and is advancing its BREASTESTplus breast cancer test towards broader clinical use.

Jcurve Solutions has reported a robust Q2FY26 with a significant profit turnaround and a confident revenue outlook for FY26, driven by strong sales and recurring revenue growth.

Lake Resources has clarified its latest cash flow report, highlighting $666k spent on environmental and power solution explorations while advancing key regulatory approvals for its Kachi lithium project. The company maintains a robust liquidity position and benefits from new technology partnerships aimed at reducing costs.

Island Pharmaceuticals has raised $9 million to advance its antiviral drug Galidesivir through the FDA’s Animal Rule pathway, targeting inclusion in the US Strategic National Stockpile for biodefense viruses.

Charter Hall Social Infrastructure REIT (CQE) reported a robust half-year performance with a 51.6% jump in statutory profit and upgraded its FY26 distribution guidance, underpinned by strategic acquisitions and refinancing.

Vitrafy Life Sciences has delivered key milestones in the first half of FY26, including a strategic partnership with IMV Technologies and progress in clinical studies, while maintaining a strong cash position to support its U.S. expansion and product launches.

Apiam Animal Health shareholders have overwhelmingly approved the proposed acquisition by Adamantem Capital-controlled entities, clearing a critical hurdle for the $500 million deal.